Behavioural Neurology

Behavioural Neurology / 2018 / Article
Special Issue

Behavioural and Cognitive Changes in Lewy Body Dementias

View this Special Issue

Research Article | Open Access

Volume 2018 |Article ID 5315098 |

Yao-Chin Wang, Po-An Tai, Tahmina Nasrin Poly, Md Mohaimenul Islam, Hsuan-Chia Yang, Chieh-Chen Wu, Yu-Chuan (Jack) Li, "Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies", Behavioural Neurology, vol. 2018, Article ID 5315098, 8 pages, 2018.

Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies

Academic Editor: Shinro Matsuo
Received14 Feb 2018
Accepted22 Apr 2018
Published10 Jul 2018


Antidepressants are the most commonly and widely used medication for its effectiveness in the treatment of anxiety and depression. A few epidemiological studies have documented that antidepressant is associated with increased risk of dementia so far. Here, our aim is to assess the association between antidepressant use and risk of dementia in elderly patients. We searched articles through MEDLINE, EMBASE, Google, and Google Scholar from inception to December 1, 2017, that reported on the association between antidepressant use and dementia risk. Data were collected from each study independently, and study duplication was checked by at least three senior researchers based on a standardized protocol. Summary relative risk (RR) with 95% CI was calculated by using a random-effects model. We selected 9 out of 754 unique abstracts for full-text review using our predetermined selection criteria, and 5 out of these 9 studies, comprising 53,955 participants, met all of our inclusion criteria. The overall pooled RR of dementia was 1.75 (95% CI: 1.033–2.964) for SSRIs whereas the overall pooled RR of dementia was 2.131 (95% CI: 1.427–3.184) for tricyclic use. Also, MAOIs showed a high rate of increase with significant heterogeneity. Our findings indicate that antidepressant use is significantly associated with an increased risk of developing dementia. Therefore, we suggest physicians to carefully prescribe antidepressants, especially in elder patients. Additionally, treatment should be stopped if any symptoms related to dementia are to be noticed.

1. Introduction

Dementia is a neurocognitive disorder characterized by cognitive impairment. As the life expectancy of people has been increasing, and the prevalence of dementia has been increasing dramatically [1], dementia, therefore, has appeared as a major cause of disability and dependence among older people which is triggering huge economic burdens around the world. In 2012, nearly 35.5 million of people had dementia, and this number is expected to be doubled by 2030 and approximately 115 million by 2050 [2, 3]. A few epidemiological studies have found the possible link between late-life depression and consistently an increased risk of dementia so far. These studies also mentioned that several factors like stroke, diabetes mellitus, hypertension, head trauma, and hyperlipidemia might be associated with dementia [4, 5].

Antidepressants are a commonly and widely used medication for its effectiveness in the treatment of anxiety and depression [6]. Despite their benefits in depression, concerns have emerged on their safety and the subsequent risk for dementia, but the results are still inconsistent. Previous studies have demonstrated that antidepressant drugs are responsible for adaptive process disruption. It is basically triggered by serotonin, reduces brain metabolism, and escalates the clinical conversion to dementia risk [7, 8]. Contrary, Schmitt et al. reported that treatment with an antidepressant like SSRIs may help to improve cognitive function in patients with Alzheimer’s dementia [9].

Until now, there is no particular meta-analysis on the association between antidepressant use and the risk of dementia among the elderly patients. We therefore conducted a meta-analysis of observational studies to evaluate the relationship between antidepressant use and dementia risk. Finding from our present meta-analysis would assist healthcare providers to improve treatment outcome and improve the existing knowledge about antidepressant therapy. In this meta-analysis, we only included studies that reported patients having exposure to antidepressants for at least one month and included patients’ mean age more than 50 years.

2. Methods

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (Supplementary Table S1) [10]. We have used similar methods in our previous published three literatures [1, 11, 12].

2.1. Database

In the initial stage, we developed in this study a search strategy by consulting with our senior researchers at the International Center for Health Information Technology lab. Our three senior pharmacists (MMI, TNP, and H-CY) are experts in systematic review and meta-analysis regarding drug-disease and disease-disease associations. We searched for articles on the electronic databases such as PubMed, EMBASE, and Scopus until December 1, 2017, which reported on the possible association between antidepressant use and dementia risk. We used the following search terms as medical subject headlines and keywords: (“Anti-depressant drugs” OR “SSRIs” OR “Tricyclics (TCAs)” OR “Monoamine oxidase inhibitors (MAOIs”) And (“Dementia risk”) (Supplementary Table S2). To find any missing article in our initial search, we conducted additional searches in the reference lists of all included full text. However, Google Scholar was used to finding academic articles citing eligible articles. After assembling all potential articles, we then used EndNote X7 (Thomson Reuters) to manage and remove the duplicates.

2.2. Eligibility Criteria

Firstly, our authors independently screened all titles and abstracts of all retrieved articles. At the initial stage, they considered all studies published only in English. Additionally, observational study designs such as case-control, cohort, and randomized control trials that reported on antidepressant use and the risk of dementia were considered in our primary search strategy. The following criteria were considered to exclude studies if (1) they published as a letter to the editor, editorial, case study, and short communications; (2) patients had less than 30 days’ antidepressant use; and (3) studies had a less than one-year follow-up period.

2.3. Inclusion and Exclusion Criteria

In this stage, two authors (MMI and TNP) retrieved full-text articles and checked the duplication of included studies. We considered only those studies if they met the following criteria: (1)were published in English(2)reported an association between antidepressants and dementia risk(3)having at least 50 participants in both treatment and control groups(4)having results demonstrated on OR/HR with 95% CI.(5)having a more than one-year follow-up period(6)identified dementia patients with ICD-9/biochemical test or other standard procedure

However, they excluded those articles if they were not an observational study and if the participants are not patients with dementia due to antidepressants. If the study met all inclusion criteria at this stage, our two authors (MMI and TNP) further reviewed to ensure the quality of the final analysis. Any disagreements regarding quantitative information (number of participant, dementia identification, duration of therapy, etc.) between two authors (MMI and TNP) were resolved by our main supervisor (YCL) of this study. They also kept some studies for reference, if they provide valuable information regarding their associations.

2.4. Data Extraction and Risk Bias Assessment

We finally included four studies, and those two authors then garnered information from each of these four studies. They collected the following information from four included studies: (a) author name and publication years; (b) study duration, study location, and study design; (c) condition information (i.e., data source, condition definition, and the total number of participants); and (d) odds ratios/hazard ratios with 95% CI for summary calculation.

2.5. Methodological Quality Assessment

The Newcastle-Ottawa Scale (NOS) was used to evaluate the methodological quality of included observational studies (Supplementary Table S3) [13]. We evaluated included studies in three categories: selection (4 stars) and comparability (2 stars) of study groups and assessment of the outcome of interest (3 stars). The star rating system was used to indicate the quality, with 0–6 stars defined as low-quality and 7–9 stars as high-quality.

2.6. Statistical Analysis

In the final analysis, we calculated risk ratios (RRs) with 95% CIs to assess the risk of dementia with antidepressants. Odds ratios are close approximations of RR. We therefore combined odds ratios with HRs, resulting in a common estimate of RR [14]. A risk rate greater than 1 indicates an increased risk of dementia, and a risk rate smaller than 1 indicates a decreased risk of dementia. Statistical significance was evaluated using the 95% CIs. If the 95% CI did not include the neural value 1, we consider the risk statistically significant. In our study, we calculated the risk ratio (RR) from both case-control and cohort studies and used the most adjusted estimate available in each study due to estimation of a valid result.

A random-effects model was used to reduce the heterogeneity among the studies. We used comprehensive meta-analysis package (Version 3) to draw forest plots and subgroup estimation. The meta-analysis of proportion uses the binominal distribution for analysis. We quantified heterogeneity of the studies using the statistic, and its significance was determined based on the accompanying value in Cochran’s test. If the value is 0%, it indicates no heterogeneity, and increasing values represent greater amounts of heterogeneity. The values of 25%, 50%, and 75% were considered as low, moderate, and high levels of heterogeneity. However, values arising from the random-effects models were also used to quantify heterogeneity.

3. Results

3.1. Literature Search

A total of 754 records were identified through our initial database search. Of those, 745 studies were excluded based on our predetermined inclusion and exclusion criteria. We described full details in method parts. We reassessed the full text of the remaining 9 articles. Finally, 5 studies met all our inclusion criteria and were included in the final meta-analysis. A flow chart showing the study selection is presented in Figure 1.

3.2. Study Characteristics

The characteristics of the selected studies are presented in Table 1. The five included observational studies [1519] were published between 2012 [19] and 2017 [18]. Among these studies, 3 were from Asia and 2 were from North America. Three studies were cohort studies [1719], and two studies were case-control study designs [15, 16]. Two studies reported that the possible onset age of dementia was over 60 years [17, 19], and three studies reported an age of development of dementia which was below 60 years [15, 16, 18]. Almost every study mentioned antidepressant exposure, and they also evaluated the various classes of antidepressant use and dementia risk. A total of 53,955 study participants were included in our quantitative synthesis of which female patients were higher than male patients. The length of follow-up ranged from 3 to 11 years. All dementia patients were confirmed by checking the medical history, and all of the studies adjusted their results of potential confounding factors.

Author/yearCountryStudy durationStudy designAdjustmentsResults

Wei-Sheng Lee-2016 [15]Taiwan2005–2011Case-control1, 2, 3, 4, 5, 6, 7, 8, 9For SSRIs,
(95% CI: 2.27–2.71)
For MAOIs,
(95% CI: 1.47–2.36)
For TCAs,
(95% CI: 1.32–1.57),
Wei-Sheng Lee-2017 [16]Taiwan2005–2011Case-control1, 2, 3, 4, 5, 6, 7, 8, 9For SSRIs,
(95% CI: 0.50–0.69)
For TCAs,
(95% CI: 0.89, 1.17
For NGAs,
(95% CI: 3.34, 5.37)
Wang 2016 [17]USA1991–2010Cohort1, 2, 3, 6, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18For SSRIs,
(95% CI)
For non-SSRIs,
(95% CI)
Then 2017 [18]Taiwan2003–2006Cohort1, 2, 3, 4, 8, 9, 19, 20For SSRIs,
(95% CI: 2.62–5.09)
(95% CI: 2.54–8.80)
For TCAs,
(95% CI: 2.30–4.63)
For MAOIs,
(95% CI: 2.17–11.24)
Goveas 2012 [19]USA1996–2007Cohort1, 2, 3, 4, 6, 9, 10, 11, 21For SSRIs,
(95% CI: 1.01–3.10)
For TCAs,
(95% CI: 0.99–3.21).

(1) age, (2) gender, (3) diabetes, (4) hypertension, (5) stroke, (6) coronary artery disease, (7) head injury, (8) anxiety, (9) depression, (10) smoking, (11) body mass index, (12) cancer, (13) COPD, (14) liver disease, (15) hyperlipidemia, (16) renal disease, (17) thyroid disease, (18) cerebrovascular disease, (19) insomnia, (20) CCI, and (21) history of alcohol consumption.
3.3. Methodological Quality of Included Studies

The Newcastle-Ottawa Scale (NOS) was used to assessed the methodological quality of included observational studies. The mean value for the five studies was 7.8 (Table 2).


Case-control studySelectionComparabilityExposureTotal
Definition adequateRepresentativeness of the casesSelection of controlsDefinition of controlsControl for important factor or additional factorAscertainment of exposureSame method of ascertainment for cases and controlsNonresponse rate(0–9)

Wei-Sheng Lee-2017 [16]8
Wei-Sheng Lee-2016 [17]9

Note: a “star ()” system of the Newcastle-Ottawa Scale (NOS) has been developed for the methodological quality assessment: each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category.

Cohort studySelectionComparabilityExposureTotal
Selection of nonexposed cohortRepresentativeness of the cohortAscertainment of exposureOutcome of interestComparability of cohorts on the basis of the design or analysisAssessment of outcomeFollow-up long enough for outcomes to occurAdequacy of follow-up of cohorts(0–9)

Wang 2016 [17]7
Then 2017 [18]9
Goveas 2012 [19]6

Note: a “star ()” system of the Newcastle-Ottawa Scale (NOS) has been developed for the methodological quality assessment: each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category.
3.4. Meta-Analysis

In the main analysis, a total of five studies evaluated the risk between selective serotonin reuptake inhibitor (SSRI) use and development of dementia. SSRI use is significantly associated with an increased risk of dementia when compared with nonuse. The overall pooled increase of dementia in patients with SSRI use was RR 1.75 (95% CI: 1.033–2.964) with significant heterogeneity present (, ) (Figure 2).

Four studies provided the risk estimation of tricyclic (TCA) use and dementia risk. The pooled RR for dementia risk was 2.131 (95% CI: 1.427–3.184) with the patients with TCAs (Figure 3). There was also significant heterogeneity (, ) among studies.

Two studies evaluated the impact of monoamine oxidase inhibitor (MAOI) therapy and risk of dementia. The overall pooled increase of dementia in patients with MAOI use was RR 2.791 (95% CI: 1.086–7.169) with significant heterogeneity present (, ) (Figure 4).

3.5. Sensitivity Analysis

Lee et al. [15] evaluated the risk of dementia according to cumulative dose of individual antidepressants. Patients with SSRIs had higher risk of dementia [(, 95% CI: 1.80–2.31; , 95% CI: 1.85–2.39; , 95% CI: 2.60–3.37; and , 95% CI: 2.69–3.51)] for <840 mg, 841–3000 mg, 3001–10,500 mg, and >10,500 mg. Contrarily, tricyclic was associated with a decreased risk of dementia [(, 95% CI: 0.38–0.51, , 95% CI: 0.22–0.30; , 95% CI: 0.17–0.24; and , 95% CI: 0.11–0.15)] for <840 mg, 841–3000 mg, 3001–10,500 mg, and >10,500 mg, respectively. Then et al. [18] investigated gender, different age groups, and dementia risk. Males had a higher risk of developing dementia (, 95% CI: 2.64–4.88) than female patients (, 95% CI: 3.11–6.37). Additionally, patients aged 45–65 had a higher risk (, 95% CI: 4.45–15.61) than patients aged ≥65 years (, 95% CI: 2.98–4.94). Goveas et al. [19] provided information about developing adverse effects such as mild cognitive impairment (, 95% CI: 1.14–2.54) and probable dementia (, 95% CI: 0.71–2.17).

3.6. Publication Bias

In our study, we showed the visual interpretation and test for asymmetry of the funnel plot of the publications. However, it is well established that the test of asymmetry will not be reliable when the included study number is not substantial [20]. Figure 5 depicts the funnel plot, indicating the presence of publication bias. Egger’s regression test was used to present the funnel asymmetry, and it showed a highly significant publication bias ().

4. Discussion

4.1. Main Outcome

This current meta-analysis of observational epidemiological studies suggests that use of antidepressants increased a risk of developing dementia among the elderly population when compared with nonusers. Patients with monoamine oxidase inhibitor therapy had a higher risk of developing dementia than those with tricyclic and selective serotonin reuptake inhibitor therapy. Of importance, these findings would make physicians more cautious when they will consider an antidepressant treatment to their patients with depression. However, the decision to prescribe antidepressant therapy should be made in the light of the stringent clinical evaluation of benefits and risks, more particularly when physicians will prescribe antidepressants to a patient with depression. If antidepressant therapy is needed, it should be used judiciously and for the shorter period of time. Additionally, healthcare providers should routinely monitor the symptom of dementia risk factors such as memory loss, confusion, and disorientation while initiating or rewriting antidepressants to patients.

4.2. Biological Evidences

The biological mechanisms of the association between antidepressants and risk of developing dementia are still unclear. However, there are various possible ways of explanations for their association. First, the onset of depression before 65 years’ age might be linked to the development of dementia and more recent depressive symptoms might link to the prodromal phase of dementia [7, 21]. Several biological studies reported that apolipoprotein (APOE) ɛ4 is a major known genetic risk factor that synergistically interacts with depression. Their interaction enhances the possibility of dementia risk, but it is not still well established [22, 23]. Second, use of antidepressants might prompt the imbalance of various neurobiological pathways. Therefore, it could help to elevate oxidative and nitrosamine stress as well as inflammation. Additionally, it might promote mitochondrial dysfunction, increased apoptosis, and finally diminished neurotrophic support [24]. Third, Steffens et al. reported that antidepressants increase subclinical cerebrovascular disease risk and promote cognitive decline by elevating potential oxidative stress [25]. Furthermore, to confirm the possible biological mechanism/link, more experimental and biological models are warranted.

4.3. Strengths and Limitations

Our study has several strengths. First, there is an enhanced statistical power to evaluate any association between antidepressant use and dementia risk. Second, this study evaluates the association in great detail and showed an association of different categories of antidepressants. However, our study has several limitations that need to be addressed. First, we included a small number of studies in our analysis. Second, a meta-analysis of epidemiological studies always has some unmeasured or uncontrolled confounding factors from the original studies. Our study findings had some degree of heterogeneity even though we used a random-effects model in our study analysis that helps to reduce publication bias. Third, we did not provide any information regarding dose differential and risk of dementia due to an insufficient amount of information. Fourth, duration of antidepressant and dementia risk were not evaluated because of restrained data. Fifth, types of dementia risk with antidepressant use were not investigated due to lack of information. Sixth, females are more prevalent to depression and anxiety than males are, and females act differently in the metabolism and distribution of antidepressants [26, 27], but we could not categorize dementia risk on the basis of gender. Finally, we were unable to include randomized controlled trials due to the absence of data.

4.4. Recommendation

Till now, no particular treatments are available to improve cognitive and behavioral symptoms of dementia patients. Additionally, antidepressant prescription has been increasing and concerns have been increased due to antidepressant therapy. Therefore, treatment of depression patients with antidepressant therapy should be assessed on a timely basis to reduce any unfavorable effects. If any symptoms are observed, then physicians need to stop antidepressant therapy or treat patients with a low dosage or shorter period of time. It is also indispensable to inform patients or their family about the inauspicious consequence of antidepressant therapy and other treatment options available for their current physical condition. However, to ensure safe and effective treatment, it is high time to provide proper guidelines for patients and healthcare providers.

4.5. Unanswered Questions and Future Direction

Since our study summarized results from several epidemiological studies, this is why we acknowledge that findings from this study could not clarify whether the observed association between antidepressants and dementia risk is the causal effect or other unmeasured confounding variables [28]. Hence, larger long-term prospective randomized control trials and biological studies are warranted to justify a possible biological mechanism which links dementia risk or rebut their association.

5. Conclusion

To our knowledge, this meta-analysis shows the most rigorous and precise analysis regarding antidepressant use and the risk of dementia. Our findings showed a significantly increased risk of dementia with antidepressant therapy. Healthcare providers might preferentially avoid unnecessary prescription of antidepressants to the patients if any symptoms regarding dementia are noticed. Additionally, proper guidelines should be provided for quality and safety treatment.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


This work was financially supported by the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan.

Supplementary Materials

Table S1: PRISMA 2009 checklist. Table S2: search strategy. Table S3: modified Newcastle-Ottawa Scale for risk of bias assessment. (Supplementary Materials)


  1. M. M. Islam, U. Iqbal, B. Walther et al., “Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis,” Neuroepidemiology, vol. 47, no. 3-4, pp. 181–191, 2017. View at: Publisher Site | Google Scholar
  2. A. Wimo, L. Jönsson, J. Bond, M. Prince, B. Winblad, and Alzheimer Disease International, “The worldwide economic impact of dementia 2010,” Alzheimer's & Dementia, vol. 9, no. 1, pp. 1–11.e3, 2013. View at: Publisher Site | Google Scholar
  3. C. K. Wu, Y. H. Yang, T. T. Lin et al., “Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis,” Journal of Internal Medicine, vol. 277, no. 3, pp. 343–352, 2015. View at: Publisher Site | Google Scholar
  4. L. A. Profenno, A. P. Porsteinsson, and S. V. Faraone, “Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders,” Biological Psychiatry, vol. 67, no. 6, pp. 505–512, 2010. View at: Publisher Site | Google Scholar
  5. C. S. Ivan, S. Seshadri, A. Beiser et al., “Dementia after stroke: the Framingham Study,” Stroke, vol. 35, no. 6, pp. 1264–1268, 2004. View at: Publisher Site | Google Scholar
  6. C.-Y. Tsai, H.-C. Yang, M. Islam et al., “Psychotropic medications prescribing trends in adolescents: a nationwide population-based study in Taiwan,” International Journal for Quality in Health Care, vol. 29, no. 6, pp. 861–866, 2017. View at: Publisher Site | Google Scholar
  7. A. L. Byers and K. Yaffe, “Depression and risk of developing dementia,” Nature Reviews Neurology, vol. 7, no. 6, pp. 323–331, 2011. View at: Publisher Site | Google Scholar
  8. C. Shilyansky, L. M. Williams, A. Gyurak, A. Harris, T. Usherwood, and A. Etkin, “Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study,” The Lancet Psychiatry, vol. 3, no. 5, pp. 425–435, 2016. View at: Publisher Site | Google Scholar
  9. J. Schmitt, M. Wingen, J. Ramaekers, E. Evers, and W. Riedel, “Serotonin and human cognitive performance,” Current Pharmaceutical Design, vol. 12, no. 20, pp. 2473–2486, 2006. View at: Publisher Site | Google Scholar
  10. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration,” PLoS Medicine, vol. 6, no. 7, article e1000100, 2009. View at: Publisher Site | Google Scholar
  11. T. N. Poly, M. M. Islam, B. A. Walther et al., “Exploring the association between statin use and the risk of Parkinson’s disease: a meta-analysis of observational studies,” Neuroepidemiology, vol. 49, no. 3-4, pp. 142–151, 2017. View at: Publisher Site | Google Scholar
  12. M. M. Islam, H.-C. Yang, P.-A. Nguyen et al., “Exploring association between statin use and breast cancer risk: an updated meta-analysis,” Archives of Gynecology and Obstetrics, vol. 296, no. 6, pp. 1043–1053, 2017. View at: Publisher Site | Google Scholar
  13. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at: Publisher Site | Google Scholar
  14. J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions version 5.1. 0, The cochrane collaboration, 2011.
  15. C. Lee, C.-L. Lin, F.-C. Sung, J.-A. Liang, and C.-H. Kao, “Antidepressant treatment and risk of dementia: a population-based, retrospective case-control study,” The Journal of Clinical Psychiatry, vol. 77, no. 1, pp. 117–122, 2016, quiz 122. View at: Publisher Site | Google Scholar
  16. C. W.-S. Lee, C.-L. Lin, P.-Y. Lin, S. Thielke, K.-P. Su, and C.-H. Kao, “Antidepressants and risk of dementia in migraine patients: a population-based case-control study,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 77, pp. 83–89, 2017. View at: Publisher Site | Google Scholar
  17. C. Wang, S. Gao, H. C. Hendrie et al., “Antidepressant use in the elderly is associated with an increased risk of dementia,” Alzheimer Disease and Associated Disorders, vol. 30, no. 2, pp. 99–104, 2016. View at: Publisher Site | Google Scholar
  18. C.-K. Then, N.-F. Chi, K.-H. Chung et al., “Risk analysis of use of different classes of antidepressants on subsequent dementia: a nationwide cohort study in Taiwan,” PLoS One, vol. 12, no. 4, article e0175187, 2017. View at: Publisher Site | Google Scholar
  19. J. S. Goveas, P. E. Hogan, J. M. Kotchen et al., “Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the Women’s Health Initiative Memory Study,” International Psychogeriatrics, vol. 24, no. 8, pp. 1252–1264, 2012. View at: Publisher Site | Google Scholar
  20. J. P. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, 2011.
  21. A. F. Jorm, “History of depression as a risk factor for dementia: an updated review,” Australian & New Zealand Journal of Psychiatry, vol. 35, no. 6, pp. 776–781, 2016. View at: Publisher Site | Google Scholar
  22. I. K. Karlsson, A. M. Bennet, A. Ploner et al., “Apolipoprotein E ε4 genotype and the temporal relationship between depression and dementia,” Neurobiology of Aging, vol. 36, no. 4, pp. 1751–1756, 2015. View at: Publisher Site | Google Scholar
  23. X. Meng and C. D'arcy, “Apolipoprotein E gene, environmental risk factors, and their interactions in dementia among seniors,” International Journal of Geriatric Psychiatry, vol. 28, no. 10, pp. 1005–1014, 2013. View at: Publisher Site | Google Scholar
  24. A. Carvalho, K. Miskowiak, T. Hyphantis et al., “Cognitive dysfunction in depression–pathophysiology and novel targets,” CNS & Neurological Disorders - Drug Targets, vol. 13, no. 10, pp. 1819–1835, 2014. View at: Publisher Site | Google Scholar
  25. D. C. Steffens, H. Chung, K. R. R. Krishnan, W. T. Longstreth, M. Carlson, and G. L. Burke, “Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: the cardiovascular health study,” Stroke, vol. 39, no. 3, pp. 857–862, 2008. View at: Publisher Site | Google Scholar
  26. M. M. Islam, U. Iqbal, B. A. Walther et al., “Gender-based personalized pharmacotherapy: a systematic review,” Archives of Gynecology and Obstetrics, vol. 295, no. 6, pp. 1305–1317, 2017. View at: Publisher Site | Google Scholar
  27. R. Keers and K. J. Aitchison, “Gender differences in antidepressant drug response,” International Review of Psychiatry, vol. 22, no. 5, pp. 485–500, 2010. View at: Publisher Site | Google Scholar
  28. M. Kundi, “Causality and the interpretation of epidemiologic evidence,” Ciência & Saúde Coletiva, vol. 12, no. 2, pp. 419–428, 2007. View at: Publisher Site | Google Scholar

Copyright © 2018 Yao-Chin Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.